Navigation Links
Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
Date:5/7/2008

to, those related to the company's future clinical development programs and the timing thereof, the company's expected financial and operating results, future clinical development plans, the details of the clinical trials and the results and timing thereof, and the timing of regulatory applications and action. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the company's Wyeth collaboration, including Wyeth's control over development timelines and the risk that the current Phase 2b study of TRU-015 does not help the Company and Wyeth identify a TRU-015 induction dosing regimen or further establish the most effective treatment regimen for TRU-015, the risks that the Company is unable to advance its clinical development programs and regulatory applications and action at the rate it expects, the risk that the Company does not achieve the financial and operating results it expects and such other risks as identified in the company's quarterly report on Form 10-K for the period ended Dec. 31, 2007, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate Web site at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, contact:

Trubion Pharmaceuticals Inc.

Jim DeNike

Senior Director, Corporate Communication

(206) 838-0500

jdenike@trubion.com

Waggener Edstrom Worldwide Healthcare

Amy Petty

Senior Account Executive

<
'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 Research and Markets  has announced ... report to their offering. ... to diagnose, monitor, and assess medical conditions, diseases, or ... outcomes for earlier and more targeted treatment. These tests ... accurate results. This kind of diagnostics provides early detection ...
(Date:7/22/2014)... 22, 2014  Based on its recent analysis ... & Sullivan recognizes Siemens Healthcare with the 2014 ... FREEZEit solution, which employs Siemens, MAGNETOM Aera and ... motion-insensitive imaging. The solution,s sophistication and utility in ... MRI imaging in the U.S. market. ...
(Date:7/22/2014)... , July 22, 2014  PuraMed BioScience®, ... of over-the-counter (OTC) medicinal and healthcare products, announced ... of Operation Troop Aid. "We are ... Russell Mitchell , CEO and Chairman of PuraMed ... women in combat zones experience migraines much more ...
Breaking Medicine Technology:Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 2Global IVD Market 2014-2018: Key Vendors are Abbott Laboratories, Johnson & Johnson, Roche Diagnostics and Siemens Healthcare 3Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 2Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 3Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 4PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 2PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 3
... 24, 2012  Covance Inc. (NYSE: CVD ) today ... Health Care Conference on Tuesday, February  28, 2012 at 9:00 ... at www.covance.com . In order to register and download any ... Covance, with headquarters in Princeton, New Jersey, is one of ...
... products in the pipeline and more at the edge ... life of mature brands are critical to today,s pharmaceutical ... many as 10 years and billions of dollars to ... To help biopharmaceutical companies more effectively conduct ...
Cached Medicine Technology:Covance to Present at Citi 2012 Global Health Care Conference 2Report Delivers ROI Analysis on Key Lifecycle Management Strategies Utilized by the Pharmaceutical Industry 2
(Date:7/23/2014)... 23, 2014 Picnic Lunches, Residents of The ... outdoor concerts and festivals, while still dining on the fabulous ... concerts in the park or to the beach or museum ... great meal while they’re out,” said Brian Hughes, director of ... the residents are just loving.” , Hagopian, the executive chef ...
(Date:7/23/2014)... childbirth and post delivery may reduce the risk of ... perinatal psychiatrist, in a July 23 editorial in ... based on a new Chinese study that found women ... vaginal delivery had a much lower risk for postpartum ... "Maximizing pain control in labor and delivery with your ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Men and ... often spend a portion of their disposable income each ... is now promoting its best anti aging products guide ... , This products guide is now released and accessible ... Internet connection. Known retailers were selected and inserted into ...
(Date:7/22/2014)... Ticket Down is a reliable ... tickets at Sporting Park in Kansas City, MO. ... 23rd. Tickets can be conveniently printed out for this ... can be reached toll free at 1-877-870-3653. All tickets ... covered by Ticket Down's customer satisfaction guarantee. , About TicketDown.com: ...
(Date:7/22/2014)... (PRWEB) July 23, 2014 Recently, iFitDress.com, a ... women, has announced its new selection of white party ... announced that custom made outfits are now available on its ... order before the end of July can get a discounted ... company’s products are popular among international customers, so its marketing ...
Breaking Medicine News(10 mins):Health News:Chicago’s The Clare Retirement Community Announces New Summertime Culinary Programs 2Health News:Controlling childbirth pain tied to lower depression risk 2Health News:Best Anti Aging Products Guide Launched for Natural Product Buyers Online at News Portal 2Health News:Sporting Kansas City vs. Manchester City Tickets: Ticket Down Has Slashed Ticket Prices for Manchester City vs. Sporting Kansas City on July 23rd 2Health News:Elegant White Party Dresses Now Provided by Distinguished Company iFitDress.com 2
... As part of its efforts to improve the ... U.S. Pharmacopeial (USP) Convention this week reached three ... Because Chinese manufacturers supply so much of the ... three previous agreements between USP and other government ...
... Ca2+/calmodulin-dependent protein kinase II alpha (CaMKII alpha) is an ... substrates to modify their functions. CaMKII alpha is ... brain, and is believed to be an essential mediator ... causative role of the enzymatic activity of CaMKII alpha ...
... speeds up the potty process, researchers say , FRIDAY, June ... trying to get toddlers to pee in the toilet. Now, ... century solution -- electronics. , Researchers at the University of ... especially day care attendants, when tots do their business in ...
... How to Reform Personalities Enduring Metaphysical "Black Hole" , ... question of whether intelligence is hereditary has always shared ... research studies that show cognitive differences across racial lines. ... Physical Violence" ( published by AuthorHouse ), ...
... Kensey Nash Corporation (Nasdaq: KNSY ), ... technologies for a wide range of medical procedures, announced ... rights plan. The rights plan is designed to protect ... practices or takeover bids and to prevent an acquiror ...
... to Advance Palliative Care Director, Diane E. Meier, MD, Points ... YORK, June 19 Nancy-Ann DeParle, Director of the White ... in a series of White House health care stakeholder discussions ... Care (CAPC) director, Diane E. Meier, MD, was asked to ...
Cached Medicine News:Health News:Drive for good quality medicines, foods reinforced by USP agreements with Chinese drug authorities 2Health News:Generation of a severe memory-deficit mutant mouse by exclusively eliminating the kinase activity of CaMKIIalpha 2Health News:Toilet Training Goes High Tech 2Health News:Toilet Training Goes High Tech 3Health News:Provocative New Nonfiction Addresses Spiritual Destiny 2Health News:Provocative New Nonfiction Addresses Spiritual Destiny 3Health News:Kensey Nash Corporation Adopts Stockholder Rights Plan 2Health News:Kensey Nash Corporation Adopts Stockholder Rights Plan 3Health News:Kensey Nash Corporation Adopts Stockholder Rights Plan 4Health News:White House Health Reform Stakeholder Discussion Brings Palliative Care to the Table 2
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
Ethicon Endo-Surgery provides disposable handheld instruments that provide reliable, precise performance every time. Our handheld instruments come in 5mm and 10mm sizes....
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
The Auto Suture™ ExtraHand™ balloon retractor is designed to be used during open surgery, gasless endoscopy, as well as endoscopy with gas insufflation....
Medicine Products: